Phase 1 results for the inhaled drug candidate ALX1 focus on safety and pharmacokinetics for the treatment of serious lung diseases.
RT’s Three Key Takeaways:
- Phase 1 Clinical Data: Vast Therapeutics will present safety and pharmacokinetic results from a Phase 1 study of its inhaled nitric oxide therapy, ALX1, at ATS 2026.
- Dual-Action Treatment: The drug candidate is a first-in-class small molecule designed to provide anti-inflammatory and anti-microbial activity for patients with serious lung diseases.
- Targeted Lung Delivery: ALX1 utilizes a novel prodrug approach to deliver nitric oxide to the lungs while aiming to avoid toxicities often associated with specific doses.
Vast Therapeutics will present late-breaking Phase 1 data for its inhaled nitric oxide (iNO) drug candidate, ALX1 at ATS 2026.
ALX1 is a first-in-class, small molecule nitric oxide prodrug designed to offer dual-action anti-inflammatory and anti-microbial activity without dose-associated toxicities, according to the company.
The presentation will focus on safety, tolerability, and dose-dependent pharmacokinetic data for the treatment, which is being developed for serious lung diseases.
The poster, titled “Inhaled ALX1 Safety, Tolerability, and Dose Dependent Pharmacokinetics in Phase 1 Study: A Novel Approach for Targeted Delivery of Nitric Oxide to the Lungs,” will be presented during the session “The Latest in Airway Symptoms and Disease.”
Paul Bruinenberg, MD, MBA, chief medical officer at Vast Therapeutics, will serve as the lead presenter. Bruinenberg and Nate Stasko, PhD, chief executive officer at Vast Therapeutics, will be available at the conference to discuss the company’s nitric oxide delivery technology.
